http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101974015-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_078cb8366425c7f7bb46338421d23406
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
filingDate 2010-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe26a7b1575ada6465c49739828cf28f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3702f8870937fa1f3ae4fad7906091cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_378a8776c5172af19930a01e99b45b38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96eb91a1822af6d6c06aa1a9b8bc1e58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_274dd2f2a8660f58111f68cd72f82c28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_600bebacadde06863ae23c67f199beab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ee5c05d6228156f36f04564df610a3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_519300eb184cc9f9965e0558ca7b610b
publicationDate 2011-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101974015-A
titleOfInvention Esters, their preparation methods and uses
abstract The invention discloses a class of ester derivatives with the structure of formula I and pharmaceutically acceptable salts thereof. Wherein, R 1 is halogen; R 2 , R 3 , R 4 are simultaneously or separately: hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen, nitro, nitrile, phenyl ; R 5 is: hydrogen, C 1 -C 4 linear or branched chain alkyl, halogen, nitro, nitrile, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino, C 1 -Phenyl substituted by C 4 alkanoyl amido; R 6 is: C 1 -C 4 straight chain or branched chain alkyl. The invention also discloses the preparation method of the above-mentioned compound, and at the same time discloses the pharmaceutical composition using the compound or its pharmaceutically acceptable salt as the active ingredient, and their use as anti-platelet aggregation drugs, especially in the preparation of The application of drugs for the prevention or treatment of coronary syndrome, myocardial infarction, myocardial ischemia and other cardiovascular and cerebrovascular diseases caused by platelet aggregation.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107304215-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103665042-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102757426-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102775421-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103665042-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102503953-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102503953-B
priorityDate 2010-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101402641-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4529596-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465023178
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465986202
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164132233
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163467419

Total number of triples: 33.